TITLE

The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants

AUTHOR(S)
Volk, Jonathan E; Hessol, Nancy A; Gray, Glenda E; Kublin, James G; Churchyard, Gavin J; Mlisana, Koleka; Nchabeleng, Maphoshane; Buchbinder, Susan P; Bekker, Linda-Gail
PUB. DATE
April 2014
SOURCE
International Journal of STD & AIDS;Apr2014, Vol. 25 Issue 5, p332
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
By comparing younger to older participants enrolled in a HIV vaccine efficacy trial, we aimed to gain insights into the inclusion of adolescents in future trials. This was a sub-analysis of a multisite HIV vaccine randomized clinical trial in South Africa, conducted January–September 2007. Motivations for trial enrolment, social harms, adverse events and loss to follow-up were compared between younger (18–20 years old) and older participants (21–35 years old). Both younger (n = 238) and older participants (n = 563) were equally likely to report enrolling for altruistic reasons. Younger females were less likely than older participants to join for trial reimbursement (p = 0.005), while younger males were more likely to enrol because the vaccine may provide protection from HIV-acquisition (p < 0.001). There were no significant differences in the number of social harms reported. Compared to males over 20 years old, 18–20-year-old females were less likely to experience adverse events (OR = 0.1, CI 0.01–0.80) and no more likely to be lost to follow-up (OR = 0.7, CI 0.39–1.25), while 18–20-year-old males were no more likely to experience adverse events (OR = 1.3, CI 0.58–2.83) or loss to follow-up (OR = 0.8, CI 0.51–1.41). Our data support the inclusion of younger participants who are at risk for HIV in future HIV vaccine efficacy trials.
ACCESSION #
95097440

 

Related Articles

  • Adaptive Clinical Trials: What the Doctor Ordered for HIV Vaccines. Breindl, Anette // BioWorld Insight;4/25/2011, Vol. 19 Issue 17, p3 

    The article focuses on the use of adaptive trials in clinical testing for an effective HIV vaccines. It mentions that the purpose of the testing is to bring both development times down and success rates up in adapting the trial as data by the use of trial methods. Moreover, a discussion of how...

  • NIH Researchers Face New Budget Challenges, says NIAID Director Fauci.  // Clinical Infectious Diseases;4/15/2005, Vol. 40 Issue 8, preceding p1 

    The article reports that National Institutes of Health (NIH) annual budget is expected to increase at a much slower annual rate next year, after several years of substantial growth, the director of the National Institute of Allergy and Infectious Disease (NIAID) said. To this end, numerous...

  • HIV vaccine trials planned for Africa. Birmingham, Karen // Nature Medicine;Aug2000, Vol. 6 Issue 8, p844 

    Reports on the plan of clinical trials for vaccine of HIV in Africa according to announcement of immunologist Andrew McMichael in XIIIth World AIDS Conference in Durban for the approval of human testing of HIV vaccine. Schedule for the clinical trials in Africa; Aid given by the U.S. National...

  • Research Benefits for Hypothetical HIV Vaccine Trials: The Views of Ugandans in the Rakai District. GRADY, CHRISTINE; WAGMAN, JENNIFER; SSEKUBUGU, ROBERT; WAWER, MARIA J.; SERWADDA, DAVID; KIDDUGAVU, MOHAMMED; NALUGODA, FRED; GRAY, RONALD H.; WENDLER, DAVID; QIAN DONG; DIXON, DENNIS O.; TOWNSEND, BRYAN; WAHL, ELIZABETH; Emanuel, Ezekiel J. // IRB: Ethics & Human Research;Mar/Apr2008, Vol. 30 Issue 2, p1 

    The article explores the perception of residents in the Rakai district of Uganda on the research benefits of a hypothetical HIV/AIDS vaccine trial. It specifically explores Ugandans' views on the benefits of the clinical study, in terms of the compensation to individual study participants and...

  • HIV vaccine shows some success in Thailand. Leslie, Joey // Out & About;Oct2009, Vol. 8 Issue 10, p20 

    The article discusses the study which demonstrates the result of Phase III clinical trial demonstrating the safety and modest effectiveness of investigational HIV vaccine to prevent infection in Thailand. It notes that the result released by the U.S. Army Surgeon General showed that ALVACReg HIV...

  • Phase I Trials of Preventive HIV/AIDS Vaccines Worldwide (August 2007).  // AIDS Alert;Oct2007, Vol. 22 Issue 10, p4 

    A list of Phase I trials of preventive HIV/AIDS vaccines worldwide, as of August 2007.

  • Researchers halt HIV vaccine trial -- What's the next step? Bower, Rebecca // AIDS Alert;Jan2008, Vol. 23 Issue 1, p8 

    The article reports on the cessation of an HIV vaccine clinical trial conducted by Merck & Co.

  • Some statistical issues in the design of HIV-1 vaccine and treatment trials. Gilbert, P.B. // Statistical Methods in Medical Research;Jun2000, Vol. 9 Issue 3, p207 

    This article summarizes material on statistical issues in the design of HIV-1 preventive vaccine trials and antiretroviral HIV-1 treatment trials that was presented at the first school on Modern Statistical Methods in Medical Research, held at the International Centre for Theoretical Physics in...

  • Merck HIV Vaccine Ineffective in Clinical Trial.  // Internal Medicine Alert;11/15/2007, Vol. 29 Issue 21, p2 

    The article reports on the announcement from Merck pharmaceutical company that their HIV vaccine is ineffective in a large clinical trial and that the company has terminated further test vaccinations.

  • Early Results of Therapeutic AIDS Vaccine Show Benefit. Kingman, Sharon // BioWorld International;11/17/2010, Vol. 15 Issue 45, p1 

    This article reports on the success of a Phase II trial of a therapeutic HIV vaccine conducted in Rome, Italy. The study involved giving a vaccine made from recombinant biologically active Tat protein. It has been expanded to recruit more participants. The implications of the study are discussed...

Share

Other Topics